Pharma Stability: Insights, Guidelines, and Expertise
Data manipulation refers to any unauthorized change, deletion, or fabrication of original test data, metadata, or records. In the context of stability testing, this includes:
Click to read the full article.
In 2018, the U.S. Food and Drug Administration (FDA) released the “Data Integrity and Compliance with CGMP Guidance for Industry.” It highlighted repeated inspection findings in data manipulation, missing raw data, and inadequate audit trails. The agency stressed adherence to:
Click to read the full article.
The foundation of any data integrity training module should begin with a solid understanding of the ALCOA+ principles. ALCOA stands for:
Click to read the full article.
In the pharmaceutical industry, data integrity is the cornerstone of quality, especially in stability testing. Every temperature reading, pH log, and assay result must reflect not only scientific accuracy but also ethical data capture. Regulatory agencies like the USFDA have consistently highlighted the need for documented, tamper-proof, and traceable data during inspections. As a result, structured training on data integrity has become a mandatory requirement.
Click to read the full article.
The case revolves around a mid-sized pharmaceutical manufacturer that submitted stability data in support of an ANDA (Abbreviated New Drug Application). During a routine FDA inspection, significant discrepancies were observed between the raw data and the summary reports submitted to regulatory authorities. Specifically:
Click to read the full article.
Stability testing generates long-term data under ICH climatic conditions to evaluate the shelf-life and performance of pharmaceutical products. If this data is lost due to power outages, software failures, or cyberattacks, it can halt regulatory submissions, trigger warning letters, or even lead to product recalls.
Click to read the full article.
The pharmaceutical industry has undergone a profound transformation in its data management practices. Nowhere is this more evident than in the realm of stability testing, where digital platforms have largely replaced traditional paper-based records. This evolution demands robust electronic recordkeeping standards to ensure data integrity, audit readiness, and global regulatory compliance.
Click to read the full article.
In today’s regulatory climate, internal audits are a cornerstone of pharmaceutical quality systems. When it comes to stability testing, these audits take on even greater importance as the resulting data supports shelf life, storage conditions, and safety of drug products. Ensuring data integrity through systematic internal audits helps detect and correct issues before external regulators, such as the CDSCO or USFDA, step in.
Click to read the full article.
Metadata plays a critical role in maintaining the integrity, traceability, and compliance of pharmaceutical stability testing data. In regulated environments, especially under USFDA or EMA guidelines, it is no longer enough to preserve raw data alone. Organizations must also maintain a comprehensive record of all modifications made to that data — including who made the change, when, and why.
Click to read the full article.
One of the most frequent issues encountered is missing or skipped stability time points. For instance, a 36-month stability study may show no records for the 18-month pull — either due to oversight or data loss. These gaps raise immediate concerns during audits:
Click to read the full article.